131 related articles for article (PubMed ID: 24279440)
1. [The new blood test bio-marker SEPT9 and colorectal carcinoma screening].
Beneš Z; Sedivcová M; Antoš Z; Kohout P; Puškárová G; Cerník M; Rozmahel M; Shánělová M; Dolina J; Hep A; Trubač M; Stehlík J; Vaněček T; Michal M; Simša J; Kala Z
Vnitr Lek; 2013 Nov; 59(11):971-6. PubMed ID: 24279440
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
5. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors.
Song L; Wang J; Wang H; Chen Y; Jia J; Guo S; Liu H; Peng X; Xiao W; Gong Y; Yang B; Lu Y; Li Y
Epigenomics; 2018 Dec; 10(12):1569-1583. PubMed ID: 30426784
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Church TR; Wandell M; Lofton-Day C; Mongin SJ; Burger M; Payne SR; Castaños-Vélez E; Blumenstein BA; Rösch T; Osborn N; Snover D; Day RW; Ransohoff DF;
Gut; 2014 Feb; 63(2):317-25. PubMed ID: 23408352
[TBL] [Abstract][Full Text] [Related]
7. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
Jin P; Kang Q; Wang X; Yang L; Yu Y; Li N; He YQ; Han X; Hang J; Zhang J; Song L; Han Y; Sheng JQ
J Gastroenterol Hepatol; 2015 May; 30(5):830-3. PubMed ID: 25471329
[TBL] [Abstract][Full Text] [Related]
8. Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery.
Ma ZY; Law WL; Ng EKO; Chan CSY; Lau KS; Cheng YY; Shin VY; Kwong A; Leung WK
Sci Rep; 2019 Jul; 9(1):10326. PubMed ID: 31316143
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of blood diagnostic markers in colorectal cancer.
Nikolaou S; Qiu S; Fiorentino F; Rasheed S; Tekkis P; Kontovounisios C
Tech Coloproctol; 2018 Jul; 22(7):481-498. PubMed ID: 30022330
[TBL] [Abstract][Full Text] [Related]
10. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer.
Song L; Guo S; Wang J; Peng X; Jia J; Gong Y; Yang B; Xiao W; Dong C; Liu H; Li Y
Biomark Med; 2018 Sep; 12(9):961-973. PubMed ID: 30043648
[TBL] [Abstract][Full Text] [Related]
11. Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.
Jiang H; Yu Q; Chen X; Zhang C; Shen J; Shen M; Yang Y; Wang B; Pan B; Guo W
J Clin Lab Anal; 2021 Nov; 35(11):e24030. PubMed ID: 34591323
[TBL] [Abstract][Full Text] [Related]
12. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
Fu B; Yan P; Zhang S; Lu Y; Pan L; Tang W; Chen S; Chen S; Zhang A; Liu W
Dis Markers; 2018; 2018():6437104. PubMed ID: 29849824
[TBL] [Abstract][Full Text] [Related]
13. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
14. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
15. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study.
Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW
Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763
[TBL] [Abstract][Full Text] [Related]
16. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
[TBL] [Abstract][Full Text] [Related]
17. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
Payne SR
Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
[TBL] [Abstract][Full Text] [Related]
18. mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV Colorectal Cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery.
Liu W; Hu P; Liu J; Chen L
J Surg Res; 2021 Nov; 267():485-494. PubMed ID: 34246842
[TBL] [Abstract][Full Text] [Related]
19. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
Song L; Li Y
Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
[TBL] [Abstract][Full Text] [Related]
20. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
